Currently known predictors of NSCLC include programmed cell death ligand 1 expression in tumor tissue, tumor mutation burden, tumor-infiltrating lymphocytes, gut microbiota, and TLS [9], which forms new opportunities for cancer therapy. The gene discussed is CD274; the disease is neoplasm.